H5N8候选疫苗IDCDC-RG43A在小鼠和雪貂模型中的临床前效力评估
本研究评估了基于鸡胚制备的灭活全病毒H5N8候选疫苗IDCDC-RG43A的保护效力和免疫原性,该疫苗含A/gyrfalcon/Washington/41088-6/2014的HA和NA基因。小鼠接种至少3.0 µg/剂(含氢氧化铝佐剂)后完全抵御致死性H5N8攻击并清除组织内病毒复制,雪貂接种后诱导针对clade 2.3.4.4 H5N8/H5N6的高抗体滴度并减轻临床症状和病毒扩散。
要点
- 小鼠接种至少3.0 µg/剂IDCDC-RG43A加氢氧化铝佐剂可完全保护致死性H5N8攻击。
- 雪貂接种后诱导针对clade 2.3.4.4 H5N8/H5N6的高抗体滴度。
- 雪貂抗体对clade 2.2 H5N1有高交叉反应,但对clade 1和2.3.4病毒无交叉反应。
核心结论
- IDCDC-RG43A疫苗在小鼠和雪貂中具有保护效力和免疫原性,可作为大流行前疫苗进一步临床研究。
研究设计与样本
- 评估基于鸡胚制备的灭活全病毒H5N8疫苗IDCDC-RG43A,含A/gyrfalcon/Washington/41088-6/2014的HA和NA基因,在小鼠和雪貂模型中进行临床前效力与免疫原性研究。
主要发现
- 小鼠接种至少3.0 µg/剂IDCDC-RG43A加氢氧化铝佐剂后完全抵御致死性小鼠适应H5N8攻击,并清除肺、脑、脾和肾组织中的病毒复制。
- 雪貂接种后诱导针对clade 2.3.4.4 H5N8/H5N6病毒的高抗体滴度,血凝抑制和血清中和试验显示对clade 2.2 H5N1有高交叉反应,但对clade 1和2.3.4病毒无交叉反应。
- 雪貂接种疫苗后,高剂量maH5N8攻击下临床症状减轻,病毒向肺、脾和肾等外周器官的扩散减少。
关键数值与推荐
- 小鼠免疫至少3.0 µg/剂IDCDC-RG43A加氢氧化铝佐剂可完全保护致死性攻击。
临床怎么用
- 该候选疫苗的保护和免疫原性特征支持其作为潜在大流行病毒的临床前疫苗进一步开展临床试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Because H5N1 influenza viruses continuously threaten the public health, the WHO has prepared various clades of H5N1 mock-up vaccines as one of the measures for pandemic preparedness. The recent worldwide outbreak of H5Nx virus which belongs to clade 2.3.4.4 and of which H5N6 subtype belongs and already caused human infection also increases the need of pandemic vaccine for such novel emerging viruses. In this study, we evaluated the protective efficacy and immunogenicity of an egg-based and inactivated whole-virus H5N8 (IDCDC-RG43A) developed by CDC containing HA and NA gene of the parent virus A/gyrfalcon/Washington/41088-6/2014. Mice vaccinated two times elicited low to moderate antibody titer in varying amount of antigen doses against the homologous H5N8 vaccine virus and heterologous intra-clade 2.3.4.4 H5N6 (A/Sichuan/26221/2014) virus. Mice immunized with at least 3.0 µg/dose of IDCDC-RG43A with aluminum hydroxide adjuvant were completely protected from lethal challenge with the mouse-adapted H5N8 (A/Environment/Korea/ma468/2015, maH5N8) as well as cleared the viral replication in tissues including lung, brain, spleen, and kidney. Vaccinated ferrets induced high antibody titers against clade 2.3.4.4 H5N8/H5N6 viruses and the antibody showed high cross-reactivity to clade 2.2 H5N1 but not to clade 1 and 2.3.4 viruses as measured by hemagglutinin inhibition and serum neutralization assays. Furthermore, administration of the vaccine in ferrets resulted in attenuation of clinical disease signs and virus spread to peripheral organs including lung, spleen, and kidney from high dose challenge with maH5N8 virus. The protective and immunogenic characteristic of the candidate vaccine are essential attributes to be considered for further clinical trials as a pre-pandemic vaccine for a potential pandemic virus.
引用
- Jeong JH, Kim EH, Lloren KKS, et al. Preclinical evaluation of the efficacy of an H5N8 vaccine candidate (IDCDC-RG43A) in mouse and ferret models for pandemic preparedness. Vaccine. 2018. PMID: 30502069. doi:10.1016/j.vaccine.2018.11.064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。